• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于化学特征药效团和对接方法研究组蛋白去乙酰化酶抑制剂的同工型选择性。

Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.

机构信息

Department of Organic Chemistry, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, PR China.

出版信息

Eur J Med Chem. 2010 May;45(5):1777-91. doi: 10.1016/j.ejmech.2010.01.010. Epub 2010 Jan 28.

DOI:10.1016/j.ejmech.2010.01.010
PMID:20153566
Abstract

A three dimensional (3D) chemical feature based pharmacophore model was developed for selective histone deacetylase 1 (HDAC1) inhibitors, which provides an efficient way to discuss the isoform selectivity of HDAC inhibitors. In contrast to the classical pan-HDAC pharmacophore, two hydrophobic features (HY and HYAr2) were found in the chemical feature based pharmacophore model, which might be responsible for the selectivity of HDAC1 inhibitions. Molecular docking also highlighted the two hydrophobic features, which are located in the internal cavity adjacent to the active site. The results contribute to our understanding of the molecular mechanism underlying the selectivity of HDAC1 inhibitors and suggest a possible target region to design novel selective HDAC1 inhibitors.

摘要

针对选择性组蛋白去乙酰化酶 1(HDAC1)抑制剂,建立了一个三维(3D)化学特征药效团模型,为探讨 HDAC 抑制剂的同型选择性提供了有效途径。与经典的泛 HDAC 药效团模型不同,在基于化学特征的药效团模型中发现了两个疏水性特征(HY 和 HYAr2),这可能是 HDAC1 抑制剂选择性的原因。分子对接也突出了这两个位于靠近活性位点的内部腔中的疏水性特征。这些结果有助于我们理解 HDAC1 抑制剂选择性的分子机制,并为设计新型选择性 HDAC1 抑制剂提供了一个可能的靶区。

相似文献

1
Investigation on the isoform selectivity of histone deacetylase inhibitors using chemical feature based pharmacophore and docking approaches.基于化学特征药效团和对接方法研究组蛋白去乙酰化酶抑制剂的同工型选择性。
Eur J Med Chem. 2010 May;45(5):1777-91. doi: 10.1016/j.ejmech.2010.01.010. Epub 2010 Jan 28.
2
Docking of hydroxamic acids into HDAC1 and HDAC8: a rationalization of activity trends and selectivities.将羟肟酸对接进入 HDAC1 和 HDAC8:对活性趋势和选择性的合理化解释。
J Chem Inf Model. 2009 Dec;49(12):2774-85. doi: 10.1021/ci900288e.
3
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).利用选择性组蛋白去乙酰化酶1/组蛋白去乙酰化酶2抑制剂(SHI-1:2)对组蛋白去乙酰化酶(HDAC)内腔进行探索。
Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8. doi: 10.1016/j.bmcl.2007.12.031. Epub 2008 Jan 7.
4
Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.迈向选择性组蛋白去乙酰化酶抑制剂设计:人类I类组蛋白去乙酰化酶的同源建模、对接研究及分子动力学模拟
J Med Chem. 2005 Nov 3;48(22):6936-47. doi: 10.1021/jm0505011.
5
Structural origin of selectivity in class II-selective histone deacetylase inhibitors.II类选择性组蛋白去乙酰化酶抑制剂选择性的结构起源
J Med Chem. 2008 May 22;51(10):2898-906. doi: 10.1021/jm7015254. Epub 2008 Apr 16.
6
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling.通过药效团模型鉴定HDAC抑制剂的关键配体特征
J Mol Graph Model. 2008 Apr;26(7):1160-8. doi: 10.1016/j.jmgm.2007.10.007. Epub 2007 Oct 23.
7
Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.苯甲酰胺衍生物作为组蛋白去乙酰化酶抑制剂的设计、合成与对接研究。
Bioorg Med Chem Lett. 2011 Aug 15;21(16):4924-7. doi: 10.1016/j.bmcl.2011.06.001. Epub 2011 Jun 16.
8
Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors.基于药效团和定量构效关系研究设计新型组蛋白去乙酰化酶 2 抑制剂。
Chem Biol Drug Des. 2012 May;79(5):760-70. doi: 10.1111/j.1747-0285.2012.01341.x. Epub 2012 Feb 15.
9
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.一种具有双重 DNA 结合和组蛋白去乙酰化酶抑制活性的新型抗癌双功能铂类药物候选物。
Chem Commun (Camb). 2009 Nov 28(44):6735-7. doi: 10.1039/b916715c. Epub 2009 Oct 12.
10
Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses.吲哚酰胺类似物作为强效组蛋白脱乙酰酶抑制剂的结合模式探索及三维定量构效关系分析。
Bioorg Med Chem. 2005 Sep 15;13(18):5424-34. doi: 10.1016/j.bmc.2005.05.016.

引用本文的文献

1
Discovery of New Uracil and Thiouracil Derivatives as Potential HDAC Inhibitors.新型尿嘧啶和硫脲嘧啶衍生物作为潜在组蛋白去乙酰化酶抑制剂的发现。
Pharmaceuticals (Basel). 2023 Jul 6;16(7):966. doi: 10.3390/ph16070966.
2
New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death.新型含二酮哌嗪基团的 5-芳基取代 2-氨基苯甲酰胺类 HDAC 抑制剂及其对缺血诱导的神经元细胞死亡的改善作用。
Sci Rep. 2018 Jan 23;8(1):1400. doi: 10.1038/s41598-018-19664-9.
3
Combinatorial Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders.
用于识别在抑制结构相同的HDAC1和HDAC2酶以有效治疗神经系统疾病的化疗过程中潜在热点的组合策略。
Front Mol Neurosci. 2017 Nov 9;10:357. doi: 10.3389/fnmol.2017.00357. eCollection 2017.
4
A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.一种合理的方法,用于鉴定非羟肟酸类 HDAC6 选择性抑制剂。
Sci Rep. 2016 Jul 12;6:29086. doi: 10.1038/srep29086.
5
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.通过支架融合混合查询发现一种新型组蛋白去乙酰化酶2(HDAC2)抑制剂。
Comb Chem High Throughput Screen. 2015;18(7):693-700. doi: 10.2174/1386207318666150706103918.
6
Synthesis and sar study of diarylpentanoid analogues as new anti-inflammatory agents.作为新型抗炎剂的二芳基戊烷类似物的合成及构效关系研究
Molecules. 2014 Oct 9;19(10):16058-81. doi: 10.3390/molecules191016058.
7
Insights from comprehensive multiple receptor docking to HDAC8.从综合多种受体对接角度探究 HDAC8。
J Mol Model. 2012 Aug;18(8):3927-39. doi: 10.1007/s00894-011-1297-8. Epub 2012 Mar 20.